Sunesis Licenses FBLD Technology To Carmot

Carmot is expected to use the FBLD technology, called ‘Chemotype Evolution,’ for identifying drug candidates in a broad range of therapeutic areas, including inflammatory, metabolic, and neurodegenerative diseases. Sunesis retains full rights to the technology for use in its future internal discovery efforts. Terms of the agreement were not disclosed.

Eric Bjerkholt, senior vice president of corporate development and finance at Sunesis, said: “This agreement reflects our strategy to leverage the value of our non-core assets while focusing our resources on advancing voreloxin into a pivotal Phase 3 trial in acute myeloid leukemia later this year.

“The FBLD discovery technology has the potential to generate compounds which may not be identified through traditional means of drug discovery. We are pleased that we can capitalise on Carmot’s use of the technology to advance its research activities while at the same time retain full rights to use the platform technology for our own internal research applications.”